Skip to main
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sutro Biopharma is a clinical-stage drug discovery and development company that manufactures next-generation protein therapeutics for the treatment of cancer and autoimmune disorders. The company's recent positive developments, including encouraging early data for its lead candidate STRO-004 and a favorable safety profile indicative of a differentiated therapeutic index, support a potentially broader clinical and commercial potential. The company's strong pipeline of other promising candidates, like STRO-006 and STRO-227, in addition to its strategic collaborations and robust cash position, position Sutro for long-term success and warrant a "Buy" rating.

Bears say

Sutro Biopharma is poised to benefit from its unique cell-free protein synthesis platform and diverse pipeline of drug candidates, but the company faces significant headwinds including fierce competition in the cancer therapeutics industry, regulatory and commercial risks, and potential need for additional financing in the future. They have demonstrated a strong financial position with a cash balance of $202.6M as of 1Q26, but their net loss has narrowed to $38.5M indicating continued financial challenges. Additionally, the safety profile of their key drug candidate STRO-004 appears to be weaker than that of its competitors.

STRO has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 9 analysts, STRO has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.